Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
Intervention Model: Single Group Assignment, Masking: Open Label
Response rate to treatment
A 30% response rate (complete or partial response) to treatment is expected. The response will be assessed according to RECIST criteria. This primary outcome measure is defined by the observation of at least one objective response during the treatment. This outcome measure will be correlated to biological factors.
Up to 1 year at most
Christelle DE LA FOUCHARDIERE, MD
Centre Léon Bérard
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)